<p><p>The American Cancer Society recently estimated that about 45,000 new cases of thyroid cancer will be diagnosed in the United States, with three-quarters occurring in women. The overall 5-year survival rate is about 97%, making it one of the least lethal cancers. We are experiencing an epidemic
Thyroid Cancer
โ Scribed by R. Gรถrges (auth.), H.-J. Biersack, F. Grรผnwald (eds.)
- Publisher
- Springer Berlin Heidelberg
- Year
- 2001
- Tongue
- English
- Leaves
- 307
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Table of Contents
Front Matter....Pages I-XX
Front Matter....Pages 1-1
The Changing Epidemiology of Thyroid Cancer....Pages 3-25
Histopathology, Immunohistochemistry, and Molecular Biology....Pages 27-53
Familial Differentiated Carcinoma of the Thyroid....Pages 55-67
The Diagnosis of Thyroid Cancer....Pages 69-79
The Current Surgical Approach to Non-Medullary Thyroid Cancer....Pages 81-89
Front Matter....Pages 91-91
Radioiodine Therapy for Thyroid Cancer....Pages 93-120
Percutaneous Radiation Therapy....Pages 121-129
Thyroid Cancer: Treatment with Thyroid Hormone....Pages 131-138
Treatment with Cytotoxic Drugs....Pages 139-151
Redifferentiation Therapy of Thyroid Carcinomas with Retinoic Acid....Pages 153-163
Follow-up of Patients with Well-Differentiated Thyroid Cancer....Pages 165-180
Functional Imaging of Thyroid Cancer....Pages 181-192
Magnetic Resonance Imaging....Pages 193-224
Thyroid Cancer in Chernobyl Children....Pages 225-235
Front Matter....Pages 237-237
Diagnosis of Medullary Thyroid Cancer....Pages 239-249
Imaging in Medullary Thyroid Cancer....Pages 251-273
Therapy for Medullary Thyroid Cancer....Pages 275-284
Follow-up of Medullary Thyroid Cancer....Pages 285-294
Back Matter....Pages 295-301
โฆ Subjects
Oncology; Nuclear Medicine; Endocrinology
๐ SIMILAR VOLUMES
<p>One of the main reasons for publishing this second edition of โT- roid Cancerโ is the fact that the first edition has sold out. Furth- more, during the 4 years following the publication of the first edition in 2001, some progress, mainly in the basic sciences (molecular biology), has been made. T
<p><p>The American Cancer Society recently estimated that about 45,000 new cases of thyroid cancer will be diagnosed in the United States, with three-quarters occurring in women. The overall 5-year survival rate is about 97%, making it one of the least lethal cancers. We are experiencing an epidemic
<p>Because of its relative rarity and favorable outcome, it has not been feasible to assess medical interventions for thyroid cancer using randomized prospective trials. The approach to diagnosis and treatment relies to a great extent on information derived from retrospective studies. Overall progno
<p>The subject of this publication, thyroid cancer, was the topic chosen for the First Symposium on Clinical Oncology, orgaยญ nized by the Royal College of Radiologists, London, on 26 and 27 January 1979. The papers collected here are based on the presentations made at that meeting, but have been exp
One of the main reasons for publishing this second edition of "T- roid Cancer" is the fact that the first edition has sold out. Furth- more, during the 4 years following the publication of the first edition in 2001, some progress, mainly in the basic sciences (molecular biology), has been made. The